Medicine and Pharmacology

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Riccardo Polosa

,

Davide Capodanno

,

Giulio Geraci

,

Massimo Volpe

,

Jacob George

,

Lucia Spicuzza

,

Giovanni Li Volti

Abstract: The European Commission’s proposal COM(2026) 481 aims to strengthen cardiovascular prevention across the European Union through earlier risk detection, expanded population screening, and greater harmonisation among Member States. While its life-course perspective and focus on equitable access are commendable, this critical review—authored on behalf of the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR)—identifies key clinical and methodological limitations requiring refinement. First, evidence from WHO, ESC, and Cochrane syntheses indicates that broad population-level screening increases risk-factor detection without consistently reducing cardiovascular morbidity or mortality, risking resource diversion from high-risk patients. Second, grouping smoking, vaping, and smokeless nicotine use within a single behavioural assessment obscures substantial differences in toxicant exposure and cardiovascular risk profiles. We propose five evidence-based refinements: prioritising targeted, risk-stratified assessment over indiscriminate testing; evaluating programme success through risk-factor control and hard clinical outcomes rather than coverage targets; reserving second-line investigations for clinically indicated cases; embedding an actionable "identify–advise–treat–follow-up" smoking cessation pathway within cardiovascular health checks; and distinguishing continued exclusive smoking, dual use, complete substitution with non-combustible nicotine products, and nicotine initiation to guide proportionate clinical communication.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Andrea Sonaglioni

,

Michele Lombardo

,

Gian Luigi Nicolosi

,

Massimo Baravelli

,

Cesare Cuspidi

Abstract: Background: Risk stratification remains challenging in symptomatic patients with mitral valve prolapse (MVP), preserved left ventricular (LV) systolic function, and non-severe mitral regurgitation (MR). Thoracic geometry and exercise-derived hemodynamics may provide complementary information on cardiovascular phenotype and clinical outcomes. This study investigated their associations with retrospectively documented cardiovascular events and developed an exploratory anatomical–functional nomogram. Methods: We included 140 symptomatic adults with MVP, LV ejection fraction ≥55%, and non-severe primary MR. Thoracic morphometry and exercise stress echocardiography were performed at the index assessment. Preceding non-fatal cardiovascular events requiring emergency or hospital-based care were retrospectively reconstructed. Cox regression was used to evaluate associations with historical event occurrence and develop a nomogram estimating 3- and 5-year event-free survival within the reconstructed observation period, with bootstrap internal validation. Results: Over a reconstructed observation period of 4.86 ± 4.62 years, 40 patients (28.6%) experienced at least one qualifying event: 4/58 (6.9%) with an antero-posterior (A-P) thoracic diameter < 13 cm versus 36/82 (43.9%) with a diameter ≥13 cm. Reduced thoracic depth was associated with smaller cardiac dimensions, less severe MR, and lower exercise-derived filling and pulmonary pressures, despite reduced exercise capacity and greater symptom burden. A-P diameter (hazard ratio [HR] per cm, 1.517; 95% confidence interval [CI], 1.090–2.111; p = 0.013), peak-exercise E/e’ (HR per unit, 1.177; 95% CI, 1.024–1.352; p = 0.022), and peak-exercise systolic pulmonary artery pressure (HR per mmHg, 1.073; 95% CI, 1.005–1.145; p = 0.034) were independently associated with the reconstructed composite endpoint. The three-variable nomogram achieved an apparent Harrell's C-index of 0.804 and an optimism-corrected C-index of 0.791, although calibration deviations were observed. Conclusions: Integrating thoracic geometry with exercise-derived LV filling and pulmonary hemodynamics may improve cardiovascular phenotypic characterization in symptomatic MVP without severe MR. However, because predictor measurements followed the reconstructed events, the nomogram does not establish prospective predictive validity. Independent prospective external validation is required before clinical implementation.

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Kareem A Mohamed

,

Mohamed N Elshabrawi

,

Amr Alkasir

,

Ahmed Hanfy

,

Mohammed Saifuddin

,

William Perucki

,

Magdy Abdelhamid

Abstract: Inherited arrhythmia syndromes have traditionally been classified as either primary electrical disorders or structural cardiomyopathies, a framework that increasingly fails to capture the tissue-level abnormalities identified across this spectrum. Cardiac magnetic resonance (CMR) imaging has emerged as a pivotal tool in reframing this paradigm by combining precise ventricular phenotyping with myocardial tissue characterization. In classic channelopathies such as long QT syndrome and catecholaminergic polymorphic ventricular tachycardia, CMR remains primarily exclusionary, while in structural diseases such as arrhythmogenic and hypertrophic cardiomyopathy, it directly identifies the arrhythmogenic substrate through late gadolinium enhancement and parametric mapping. Brugada syndrome occupies an intermediate position, with emerging evidence of subtle right ventricular outflow tract abnormalities challenging its classification as a purely electrical disorder. This review examines the disease-specific diagnostic yield of CMR, its expanding role in risk stratification and implantable cardioverter-defibrillator decision-making, and future directions including artificial intelligence-driven analysis and genotype-phenotype correlation.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Cheng Hu

Abstract: Background. Abdominal aortic aneurysm (AAA) is managed by a diameter threshold, yet 61% of ruptures in contemporary cohorts occur below 55 mm and diameter-matched cohorts of ruptured and unruptured aneurysms show no difference in diameter. Existing computational approaches quantify the wall stress at a given instant but not the cumulative mechanical history of the wall. We tested whether AAA can be reproduced as a fatigue-failure process of elastin, with a discrete transition — damage exposure — separating a purely mechanical phase from a biologically amplified one. The resulting framework rests on two load-bearing components with opposed duties, a discrete exposure transition, and a five-stage progression in which compensation itself fails.Methods. We constructed a two-layer model (the Damage-Exposure Model, DEM) comprising four global state variables — elastin, collagen, junction protein and inflammation — and a 720-point circumferential spatial layer carrying wall thickness, local strength and thrombus coverage. Elastin-specific local stress was compared with elastin-specific local strength. Parameters were assigned to three tiers: 23 measured in the literature, 5 derived from literature values, and 15 calibrated to reproduce specified targets. The model was run for 76 patients whose transcriptomic module scores were mapped to individual mechanical parameters, and against seven external comparisons, three pre-specified testable inferences and a 500-run Monte Carlo analysis.Results. The model reproduces a five-stage progression at ages 20.0, 56.7, 58.7, 66.6 and 73.5 years, a rupture diameter of 55.76 mm, and a two-phase expansion pattern (36.7 years before the transition, 16.8 years after). In the 76-patient cohort, 61% of simulated ruptures occurred below 55 mm and the median rupture age was 71.5 years, against 74.0 years in a 3,642-patient national registry. Of seven external comparisons, one is an independent test, four are calibration-consistency checks and two are not valid comparisons. Of the three testable inferences, one is true by construction rather than empirically, one is contradicted by the data, and one has no discriminating power. Only 4.2% of 500 Monte Carlo parameter draws satisfied five or more of the seven comparisons.Conclusions. A fatigue-based model of elastin depletion with a discrete exposure transition reproduces the timing, the rupture diameter and the sub-threshold rupture fraction of AAA, and explains why diameter alone discriminates poorly between ruptured and unruptured aneurysms. The model is not validated: its time scale is dominated by a single calibrated parameter and fifteen parameters are not identifiable. It should be read as a quantitatively specified hypothesis with an explicit falsification path, not as a clinical prediction tool.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Josephine Kranendonk

,

Suzanne Holewijn

,

Lars L.F.G. Valke

,

Cornelis Kramers

,

Michiel C. Warlé

,

Michel M.P.J. Reijnen

,

Houshang Monajemi

Abstract: Background/objective: To investigate the association between lipoprotein(a) (Lp(a)) concentrations, peripheral arterial disease (PAD), and the occurrence of major adverse cardiovascular events (MACE), or major adverse limb events (MALE). Methods: This prospective single center cohort study included 475 patients referred to a vascular center with suspected PAD de novo between January 13th 2017 and December 27th 2019. Serum Lp(a) concentrations were measured at baseline, and electronic patients’ records were reviewed for diagnosis of PAD at baseline, and the occurrence of MACE or MALE during follow-up. MACE was defined as a composite of myocardial infarction, unplanned percutaneous coronary intervention, ischemic cerebrovascular accident, transient ischemic attack, and cardiovascular death. MALE was defined as any endovascular or open revascularization or limbrelated vascular intervention performed due to PAD. Results: Of the 475 patients, 332 patients (69.9%) were diagnosed with PAD. Patients with PAD had significantly higher median LP(a) concentrations compared to those in whom PAD was ruled out (30 [11-77] mg/dL versus 19 [9-64] mg/dL, p=0.033), without differences in other lipid parameters. During a median follow-up of 6 years, 81 patients with PAD (24.4%) experienced MACE, and 141 patients (42.5%) experienced MALE. Univariate cox regression analysis showed that serum Lp(a) concentration was not significantly associated with MACE (HR 0.909, p=0.206), nor MALE (HR 1.000, p=0.995) in patients with PAD. Multivariate cox regression showed similar results. Conclusion: Patients who were diagnosed with PAD de novo had significantly higher Lp(a) concentrations, but Lp(a) was not significantly associated with occurrence of MACE or MALE.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Praveen Kumar-M

,

A.J. Venkatakrishnan

,

Marcelo Montorzi

,

C. Michael Gibson

,

Venky Soundararajan

Abstract: Importance: In the Lp(a)HORIZON trial, pelacarsen lowered lipoprotein(a) [Lp(a)] by 78% at 12 months without reducing major adverse cardiovascular events (MACE). The neutral result raises the question of whether the cardiovascular risk associated with elevated Lp(a) in routine-care is sufficiently large to yield detectable clinical benefit in ongoing clinical trials. Objective: To quantify the association of Lp(a) with recurrent MACE and aortic valve outcomes in routine care, and to explore the implications of these associations for treatment-benefit scenarios in completed and ongoing Lp(a)-lowering trials. Design, Setting, and Participants: The study used a federated analysis of deidentified electronic health records across participating US academic medical centers. The primary retrospective cohort study analyzed adults aged 18 to 80 years with at least one Lp(a) measurement in routine care and documentation of a prior myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease as of January 1, 2017 or later. Patients were followed for up to 5 years after meeting all inclusion criteria. Exposure: Baseline Lp(a), categorized as high (at least 150 nmol/L or 70 mg/dL) or low (less than 75 nmol/L or 30 mg/dL), and assessed continuously, including analyses stratified by baseline low-density lipoprotein cholesterol (LDL-C) level. Main Outcomes and Measures: Major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, ischemic stroke, or urgent coronary revascularization, and aortic stenosis or valve replacement, with hazard ratios (HRs) derived from adjusted Cox models. Results: Among 13,894 eligible patients, 13,865 contributed follow-up to outcome analyses. MACE occurred in 412 of 3,138 patients with high and 972 of 8,200 with low Lp(a) (5-year cumulative incidence, 20.1% vs 18.3%). The adjusted HR was 1.11 (95% CI, 0.98–1.25) after adjustment for age, sex, race, ethnicity, calendar year of entry, prior care, diagnosis frequency, and type and timing of the qualifying event. There was no consistent evidence of effect modification by LDL-C. In contrast, high Lp(a) was associated with aortic stenosis or valve replacement (HR, 1.62; 95% CI, 1.11–2.36). Under the assumption that pharmacological Lp(a) lowering modifies the risk represented by the observational association, a model-based analysis yielded an illustrative HR of 0.95 (95% CI, 0.89–1.02) for the magnitude of Lp(a) reduction achieved in Lp(a)HORIZON. This estimate was compatible with the reported trial HR of 1.02 and represented a smaller benefit than the trial was powered to detect. Using trial-aligned routine-care cohorts, we then projected the treatment effects for ongoing phase 3 trials of olpasiran and lepodisiran, two Lp(a) lowering agents, based on the approximately 95% reduction in Lp(a) reported in their corresponding phase 2 trials. Under three different assumptions about the timing of clinical benefit, the modeled treatment HRs ranged from 0.94 to 0.98 for OCEAN(a)-Outcomes and 0.89 to 0.97 for ACCLAIM-Lp(a). Conclusions and Relevance: In this multicenter routine-care cohort, elevated Lp(a) showed a modest and statistically insignificant association with recurrent MACE, in contrast to a stronger association with aortic stenosis or valve replacement. Modeled projections based on the observed associations suggested that ongoing trials may not be powered to detect the estimated cardiovascular benefits of Lp(a) reduction. However, these projections do not establish the treatment effects of olpasiran or lepodisiran. The findings highlight the importance of trial population, treatment duration, and clinical endpoint selection, while supporting prospective evaluation of Lp(a)-lowering therapies for aortic valve disease.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Elvira García-de-Santiago

,

Isobel Landray

,

David Prieto-Merino

,

Alberto García-Lledo

Abstract: Background/Objectives: Air pollution (AP) has been linked to an increased risk of ischemic heart disease (IHD). Numerous studies have analysed the impact of AP on myocardial infarction (MI), yielding conflicting results that could be attributed to the selection of cases and regional differences in pollution and cardiovascular risk. Methods: The relationship between the incidence of ST-segment-MI with demonstrated culprit plaque (CP-STEMI) and the exposure to several air pollutants in previous days was studied in municipalities of the metropolitan area of Madrid (Spain, 2013-2018) using linear quasi-Poisson regressions. The municipality’s daily pollution exposure was estimated as the average of all AP measurement stations weighted by the inverse of the distance to the centroid of the municipality. Results: 4,406 CP-STEMI cases were registered. NO2 surpassed the World Health Organisation recommended level more than 50% of the days. Particulate matter <2.5 microns (PM2.5) surpassed recommended level 16% of the days and SO2 and CO none. For the two-day lag exposure model, there was a significant increase in CP-STEMI in days with an increase to the 2nd tertile vs the 1st tertile of PM2.5 (aRR 1.10, 95%CI:1.00-1.20, p=0.043). The difference between the 1st and 3rd tertiles remained positive but not significant. A clear association of CP-STEMI and cold was found, but not for the rest of pollutants. Conclusions: This study suggests an increased risk of CP-STEMI independently associated with PM2.5 and confirms the effect of cold, in a region with low risk of IHD, temperate climate and reasonably controlled levels of environmental pollution.

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Ursula Bellut-Staeck

,

Maryam Dastan

,

Juan Zhou

,

Abby Pirapaharan

,

Christian Lehmann

Abstract: This narrative review outlines potential pathophysiological mechanisms in the mammalian heart in response to chronic infrasound exposure from technical installations. Recent research findings suggest that repeated exposure to infrasound can activate the heart's mechanosensitive PIEZO-1 channels. PIEZO-1 plays an important role in cardiac contractility via modulation of Ca²⁺ release and is involved in ROS homeostasis. The increasingly widespread sources of technical infrasound - which often exhibit high sound pressure intensities at infrasonic frequencies - should be reevaluated with regard to their impact on living organisms. Experimental overexpression of cardiac PIEZO-1 in mice serves as an example of potential effects of chronic infrasound exposure on the heart. Associated reactive oxygen species (ROS) generation reveals links to inflammatory pathways. Continued PIEZO-1 (over)stimulation appears to disrupt Ca²⁺ and ROS homeostasis in the long term, ultimately resulting in cardiomyopathy and arrhythmogenicity.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Jose Ignacio Juárez Del Río

,

Stefano Urso

,

Carlota Pilar Recio Cruz

,

Jesús María González Martín

,

Lucia Doñate Bertolín

,

Arnaldo Javier Estigarribia Bernal

,

Adrián Muinelo Paul

,

Adrián Torres Clarés

,

Marina Soriano Hernández

,

Francisco Portela Torrón

Abstract: Background/Objectives: Concern about sternal wound complications limits bilateral internal thoracic artery (BITA) grafting, particularly in patients with diabetes and obesity. We evaluated the mid-term results of a program of extensive BITA grafting in the Canary Islands, the Spanish region with the highest diabetes-related mortality. Methods: We retrospectively analyzed 667 consecutive patients undergoing non-emergent, first-time, isolated multivessel coronary artery bypass grafting between 2017 and 2025; 472 (70.8%) received BITA and 195 (29.2%) single internal thoracic artery (SITA) grafting. Outcomes were compared using inverse probability of treatment weighting. Results: Half of the patients (49.8%) had diabetes. Median follow-up was 46.2 months. After weighting, BITA and SITA grafting did not differ in all-cause mortality (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.55–1.47; p = 0.68), myocardial infarction (HR 0.65; 95% CI 0.28–1.51), repeat revascularization (HR 0.76; 95% CI 0.32–1.83) or major adverse cardiovascular events (HR 0.81; 95% CI 0.52–1.25). Stroke was less frequent after BITA grafting (HR 0.24; 95% CI 0.07–0.77; p = 0.016). Sternal wound complications occurred in 8.7% vs. 6.2% of patients (odds ratio 1.45; 95% CI 0.75–2.82; p = 0.35), with no excess among patients with diabetes (8.8% vs. 8.7%). Conclusions: In a population with a high burden of diabetes, BITA grafting was delivered to 70.8% of unselected patients without a significant excess of sternal wound complications. It did not improve mid-term survival, but stroke was less frequent after BITA grafting, a hypothesis-generating finding that requires confirmation.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Marc Hendrikx

,

Annick Daniels

,

Yanick Fanton

,

Caroline De Bouver

,

Luc Jamaer

,

Jean-Luc Rummens

,

Karen Hensen

Abstract: Background: Cell therapy for chronic ischaemic cardiomyopathy remains limited by poor myocardial retention and uncertain regenerative efficacy. We evaluated the effects of delayed intramyocardial transplantation of autologous cardiac atrial stem cells in a large-animal model of established chronic myocardial infarction. Methods: Myocardial infarction was induced in Göttingen minipigs by two-hour left anterior descending coronary artery occlusion. After two months of post-infarction remodeling, animals were randomly allocated to intramyocardial transplantation of autologous cardiac atrial stem cells or control treatment. Cardiac magnetic resonance imaging and three-dimensional electromechanical mapping were performed before treatment and two months thereafter. Histological and immunofluorescence analyses assessed persistence and phenotype of transplanted cells. Results: At follow-up, left ventricular ejection fraction was preserved in treated animals but declined in controls (55 ± 9% versus 41 ± 7%; p = 0.0002). Treatment attenuated adverse ventricular remodeling, with preservation of end-systolic volume and regional wall thickening. Late gadolinium enhancement-defined infarct mass decreased from 6.2 ± 2.0 g to 4.0 ± 1.0 g in treated animals and was significantly lower than in controls at follow-up (p = 0.04). Electromechanical mapping demonstrated improved myocardial electrical viability and regional mechanical function. Transplanted cells persisted within the injured myocardium and exhibited cardiomyocyte-associated structural features. Conclusions: Delayed intramyocardial transplantation of autologous cardiac atrial stem cells attenuated adverse remodeling and was associated with improved regional myocardial structure and function in established chronic ischaemic cardiomyopathy.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Chenxi Luo

,

Caiyi Li

,

Sitong Chen

,

Chaojun Yan

,

Ying Li

Abstract: Coronary occlusion (CO) is a lethal complication of transcatheter aortic valve replacement (TAVR) (incidence, 0.35%–4.0%; in-hospital mortality, approximately 50%). Although static computed tomography thresholds (ostial height >12 mm) remain the assessment standard, CO still occurs in 14.3% of patients meeting them. We developed a biphasic digital twin (BDT) integrating systolic and diastolic electrocardiogram-gated computed tomography angiography to assess dynamic CO risk in a 71-year-old woman with severe aortic stenosis. Biphasic aortic root dynamics and bilateral virtual valve-to-coronary distance (VTC) were evaluated at two implantation depths. Ostial height varied by approximately 5%, whereas leaflet volume increased by 22.0% in diastole. Right coronary ostial displacement (4.28 mm) was 1.74-fold that of the left (2.46 mm), and the sinotubular junction rotated 8.7°. A commissural calcified mass remained stable. Implantation 5 mm deeper reduced diastolic left VTC from 8.96 to 6.54 mm (–27%) but increased systolic right VTC from 4.57 to 5.93 mm (+29%). Delayed CO occurred 30 min after extubation despite patent intra-procedural angiography; surgery confirmed calcified anchoring, stent deflection, and coronary compression. Static coronary height did not capture dynamic CO risk in this patient. BDT may support individualised, biphasic, bilateral assessment by integrating dynamic leaflet expansion, asymmetric root motion, and calcified anchoring.

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Stefano Sasso

,

Lucio Giuseppe Granata

,

Vincenzo Paragliola

,

Giuseppe Massimo Sangiorgi

,

Marcello Marchetta

Abstract: Artificial intelligence (AI) is being developed to analyze intracoronary optical coherence tomography (OCT) and intravascular ultrasound (IVUS) images. This narrative review examines applications in vessel segmentation, plaque and calcium characterization, plaque phenotyping, physiological assessment, and percutaneous coronary intervention (PCI) planning. OCT provides high-resolution assessment of superficial plaque and stent structures, whereas IVUS provides deeper vessel-wall information. Automated segmentation and quantitative measurements show promising technical performance, although results vary by model, imaging feature, and validation setting. Evidence for physiological inference and prognostic assessment remains largely observational, and diagnostic agreement or association with events does not establish that AI-guided care improves clinical outcomes. These tools may support individualized lesion assessment and procedural planning, but their clinical value requires prospective evaluation. At present, AI should be used as clinician-supervised decision support, with attention to image quality, uncertainty, and model limitations.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Ilia Davarashvili

,

Danny Dvir

Abstract: Background: Mitral regurgitation (MR) is one of the most common valvular heart diseases and is associated with substantial morbidity and mortality if left untreated. Despite guideline recommendations, many patients with significant MR do not undergo surgical or transcatheter mitral valve intervention. We aimed to identify the clinical and echocardiographic characteristics associated with mitral valve intervention. Methods: We retrospectively analyzed 1,637 consecutive patients with moderate-to-severe or severe MR evaluated at Shaare Zedek Medical Center between December 2016 and December 2021. Patients were categorized into an intervention group (n = 191) and a conservatively managed group (n = 1,446). Clinical and echocardiographic characteristics were compared using univariable and multivariable logistic regression analyses. Results: Among 1,637 patients, only 191 (11.7%) underwent mitral valve intervention. Patients receiving intervention were younger (72.8 ± 12.9 vs. 76.5 ± 14.2 years; p = 0.001), more frequently male (57.6% vs. 48.0%; p = 0.013), and more commonly of Arab ethnicity (22.5% vs. 13.1%; p < 0.001). Severe MR (68.6% vs. 40.1%; p = 0.0004) and prosthetic mitral valve (6.8% vs. 2.3%; p = 0.0004) were more common among treated patients, whereas hypertension, advanced chronic kidney disease, and previous myocardial infarction were less common. Independent predictors of intervention were younger age (OR 0.98, 95% CI 0.97–0.99; p = 0.035), Arab ethnicity (OR 2.02, 95% CI 1.24–3.29; p = 0.005), and severe MR (OR 2.87, 95% CI 1.88–4.35; p < 0.001). Conclusions: Only a small proportion of patients with significant MR underwent mitral valve intervention. Older patients and those with ischemic or renal comorbidities were more likely to be managed conservatively. Earlier referral to dedicated Heart Valve Teams may improve access to guideline-directed treatment.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Lidija Savic

,

Damjan Simic

,

Andjela Ribic

,

Andrea Ivanovic

,

Natalija Vasic

,

Ratko Lasica

,

Gordana Krljanac

,

Sanja Stankovic

,

Milana Plavsic

,

Milika Asanin

Abstract: Background/aims: To identify predictors of long-term major adverse cardiovascular events (MACE) and investigate the association between reduced kidney function (KF) and MACE in patients with diabetes mellitus (DM) presenting with STEMI as their first clinically recognized manifestation of cardiovascular disease (CVD). Methods: We analyzed 512 patients with DM and STEMI without previous CVD. KF was assessed at admission and categorized as mildly, moderately, or severely reduced. The composite endpoint (MACE) included cardiovascular death, non-fatal recurrent myocardial infarction, target vessel revascularization, and non-fatal stroke. The follow-up lasted 8 years. Results: Reduced KF was present in 312 (60.9%) patients: 175 (56.1%) had mildly, 98 (31.4%) moderately, and 39 (12.5%) severely reduced KF. MACE was more frequent among patients with reduced KF across all severity stages. Moderately and severely reduced KF were independent predictors of 8-year MACE (HR 3.12, 95% CI 1.58–6.91 and HR 5.22, 95% CI 1.68–12.70, respectively). Other independent predictors included predischarge ejection fraction < 50%, new-onset atrial fibrillation, left main stenosis, heart failure at admission, and post-procedural TIMI flow < 3. Conclusion: In patients with DM presenting with their first STEMI, moderately and severely reduced KF were associated with approximately three-fold and five-fold higher risks of 8-year MACE, respectively. Mildly reduced KF was not independently associated with MACE. Assessment of KF severity may help identify patients requiring more intensive cardiovascular and multidisciplinary follow-up after STEMI.

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Anara Abbay

,

Aidana Shindauletova

,

Timur Lesbekov

Abstract: Patient safety remains a major challenge in cardiac surgery, where cardiopulmonary bypass carries risks of residual structural lesions, hemodynamic instability, embolic events, and unrecognized technical complications. This review examines intraoperative transesophageal echocardiography as a patient-safety intervention across the pre-bypass, bypass, and post-bypass phases of adult cardiac surgery, drawing on observational studies, registry analyses, and professional society guidance. Before cardiopulmonary bypass, transesophageal echocardiography establishes baseline ventricular and valvular function, identifies previously unrecognized pathology, and may guide cannulation and operative planning. During bypass, it supports ventricular decompression, myocardial protection, cannula assessment, and the detection and clearance of intracardiac air. After bypass, it evaluates the adequacy of surgical repair and identifies residual valvular lesions, ventricular dysfunction, ischemia, intracardiac air, and aortic complications while immediate corrective intervention remains possible. Although associated changes in surgical or anesthetic management are consistently reported, their frequency varies according to procedure type, patient risk, institutional practice, and study design. Furthermore, management change is a process outcome and does not, by itself, establish improvement in patient-centered outcomes. Serious complications related to transesophageal echocardiography are uncommon, but safe use requires appropriate patient selection, contraindication screening, careful probe manipulation, standardized examination and communication, and operator competence. A phase-based approach may help surgical teams connect imaging findings with time-sensitive hazards and corrective actions. Further prospective evidence is needed to identify the procedures and patient-risk profiles in which routine rather than selective intraoperative transesophageal echocardiography provides clinically meaningful benefit.

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Leona Chazanga

,

Zixin Shi

,

Rochak Dhakal

,

Qiuying Sha

,

Qing-Hui Chen

,

Weihua Zhou

Abstract: Cardiovascular diseases (CVD) and osteoporosis pose major clinical challenges for older adults worldwide. Evidence suggests these diseases are interconnected through shared biological mechanisms and risk factors. However, differences in the associations between specific CVD subtypes and osteoporosis remain incompletely understood. We examine osteoporosis in relation to coronary artery disease (CAD) and myocardial infarction (MI), stroke, atrial fibrillation (AF), peripheral arterial disease (PAD), and heart failure (HF). The review considers epidemiological evidence, shared biological mechanisms, medication effects, and questions for future research on cardiovascular–bone interactions. Studies addressing CVD, bone mineral density (BMD), osteoporosis, or fracture outcomes were identified through PubMed and backward citation searching.Across these cardiovascular conditions, studies report associations with low BMD, osteoporosis, or hip fracture. Their magnitude and consistency vary, however, according to the CVD subtype, study population, and skeletal outcome. Proposed links include chronic inflammation, oxidative stress, vascular calcification, endocrine dysregulation, and changes in RANK/RANKL/OPG and Wnt/β-catenin signaling. Genomic approach, large population-based cohorts, and causal inference methods offer opportunities to improve understanding of the complex cardiovascular-bone interactions. Further research is needed to classify subtype-specific associations and mechanisms, assess potential causal relationships, and determine whether these insights can improve risk prediction, prevention, early detection, and management of CVDs, osteoporosis, and osteoporotic hip fractures.

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Vladislav Pajović

,

Marija Kosić

,

Mirjana Jovanović

,

Nina Japundžić-Žigon

Abstract: Cardiomyopathies represent a heterogeneous group of diseases that lead to functional and structural impairment of the myocardium, frequently culminating in heart failure. Due to ethical and technical constraints inherent to human studies, rat models have become indispensable in experimental cardiology. Transthoracic echocardiography represents one of the most commonly used methods for assessing cardiac structure and function in experimental rat models of cardiomyopathy, due to its accessibility, non-invasiveness, ease of use, safety and cost-effectiveness. Almost all echocardiographic examinations in rats require a certain level of pharmacological sedation or general anesthesia to immobilize the animal and reduce motion-induced artifacts. A review of the literature reveals that only a few anesthetics are used in experimental practice. By far the two most prevalent choices are isoflurane and the ketamine-xylazine combination. Less frequently used are pentobarbital, the tiletamine-zolazepam combination, sevoflurane, and acepromazine. However, the interpretation of echocardiographic findings in experimental animals can be significantly biased by the effects of anesthesia primarily on the autonomic nervous system and cardiac contractility. Therefore the choice of anesthetic or sedative protocol represents an important, yet insufficiently standardized, methodological variable in the echocardiographic assessment of rat models of cardiomyopathy. Here we discuss the bias introduced by the use of sedatives/anesthetics when performing echocardiography in different rat models of experimental cardiomyopathy.

Review
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Ziyad Gunga

Abstract: Median sternotomy remains the gold standard for surgical access in the majority of open-heart procedures, providing reliable exposure for complex cardiac operations. Despite advances in surgical technique and perioperative care, it continues to be associated with significant complications, including bleeding, fragile or calcified tissue and sternal instability, and surgical site infections (SSIs). These complications are not isolated but are deeply interconnected, often progressing in a vicious cycle that leads to increased morbidity, mortality, prolonged hospitalization, and substantial healthcare costs. Although the individual challenges of median sternotomy have been extensively studied, a comprehensive synthesis that conceptualizes an integrated framework for optimizing outcomes is lacking. This review proposes a novel three-pillar Comprehensive Sternotomy Management Bundle that simultaneously addresses (1) perioperative bleeding management, (2) handling of fragile or calcified tissue with robust sternal stabilization, and (3) multimodal prevention of SSI. By integrating evidence-based strategies across the preoperative, intraoperative, and postoperative phases, the bundle aims to disrupt the cycle of complications, promote secure sternal healing, reduce transfusion requirements, and accelerate recovery. This multimodal care bundle aligns with the Quintuple Aim by improving clinical outcomes, enhancing the patient and clinician experience, and reducing overall healthcare costs in an increasingly older and comorbid cardiac surgical population.

Case Report
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

A. Younes

,

C. Attenhofer Jost

,

S. Glökler

,

S. Caselli

,

S. Vesenbeckh

,

M. Giacchi

Abstract: Coronary artery fistulas (CAFs) are a rare, typically congenital coronary anomaly. They may cause myocardial ischemia through a coronary steal phenomenon. Acquired CAFs are exceptionally uncommon and are usually due to an intervention or trauma. We re-port the case of a 79-year-old man with history of clear cell renal cell carcinoma previ-ously treated with right nephrectomy in 2015. Seven years later, he underwent percu-taneous coronary intervention of severe LAD stenosis following out-of-hospital cardi-ac arrest. During follow-up, progressive exertional dyspnea and inducible lateral is-chemia led to repeated coronary angiography 15 months later revealing fistulous communications from the circumflex and right coronary arteries draining into a left pulmonary mass. Right-heart catheterization showed a small left-to-right shunt at rest (Qp/Qs 1.3). Thoracic computed tomography and biopsy confirmed a large pulmonary metastasis from clear cell renal cell carcinoma, suggesting that the fistulas developed as part of tumor angiogenesis. Transcatheter coil embolization would have been a strategy to reduce tumor perfusion and the coronary steal; however, we just limited our treatment to the tyrosine kinase inhibitor Axitinib due to the metastatic disease. This case describes a rare mechanism of acquired CAF formation in metastatic renal cell carcinoma.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Yuquan Zhou

,

Jianlin Wen

,

Jinpei Cao

,

Jiaxiang Liao

,

Guorui Li

,

Yunlong Mao

Abstract: Clearing dying cardiomyocytes by efferocytosis is required for inflammation resolution and cardiac repair after myocardial infarction (MI). Whether the three functional stages of efferocytosis (recognition, engulfment and degradation) are coordinated by the local cellular neighborhood in the human infarcted myocardium is unknown. We analyzed 24 human cardiac Visium spatial transcriptomic samples (20 MI, 4 control; 94,029 spots; 19 independent donors) from a published multi-omic map of human MI[4]. Multiview interaction-based spatial transcriptomics (MISTy) identified 12 gene programs with spot-level neighborhood dependency; donor-level aggregation showed positive neighborhood gains for 22 of 23 programs after Benjamini-Hochberg correction (FDR < 0.05), including all three efferocytosis stages[5]. Efferocytosis module activity tracked macrophage proportions (Spearman rho = 0.41-0.44). Controlling for macrophage abundance removed the engulfment-related association but left a degradation-related association with endothelial and fibroblast proportions, indicating niche-dependent regulation of the degradation stage. Distance-stratified analysis showed neighborhood effects beyond direct cell-cell contact, without simple short-range dominance. Mendelian randomization linked NR1H3, STAU1, CTSS and ITGAV expression to MI risk (FDR < 0.05)[14], and connectivity-map analysis nominated niclosamide as a candidate for reversing the efferocytosis-degradation program[15]. Model-based in silico perturbation attributed the neighborhood dependency to vascular-stromal neighbors; virtual knockout of NR1H3 predicted coordinated downregulation of efferocytosis genes. Efferocytosis subprograms are thus spatially decoupled in the human infarcted myocardium, with degradation as a niche-regulated step, providing spatial and genetic leads for targeting infarct repair.

of 78